Core Insights - Pacira BioSciences, Inc. has appointed Dr. Samit Hirawat to its Board of Directors, expanding the board to 10 members [1][2] Company Overview - Pacira is focused on delivering innovative, non-opioid pain therapies aimed at transforming patient lives [4] - The company has three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera® [4] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management applications [4] - ZILRETTA is an extended-release injectable for managing osteoarthritis knee pain [4] - iovera® is a handheld device providing immediate, long-acting, drug-free pain control [4] - Pacira is advancing a pipeline of clinical-stage assets, including PCRX-201, a gene therapy in Phase 2 development for knee osteoarthritis [4] Leadership and Expertise - Dr. Hirawat brings over 25 years of clinical development and industry expertise, previously serving as Chief Medical Officer at Bristol Myers Squibb [2][3] - His experience includes overseeing global drug development and advancing transformative therapies across various therapeutic areas [2] - Dr. Hirawat has a strong academic background with over 150 peer-reviewed publications [3]

Company Overview - Pacira's mission is to deliver innovative non-opioid pain management therapies to transform lives, focusing on patient-centered care, scientific integrity, and employee well-being [3] - The company reported unaudited sales of $726 million for the previous year and has over 800 engaged employees [3] - Pacira has helped more than 18 million patients to date [3] Product Portfolio - The flagship product of Pacira is EXPAREL, a nerve block solution [4] - Other products include ZILRETTA, a long-acting corticosteroid for osteoarthritis pain, and iovera°, a medical device utilizing cryoneurolysis for pain management [4] Patient Impact - The company highlights success stories, such as a Division 1 soccer player who opted for a non-opioid solution due to family issues with opioid abuse, demonstrating the effectiveness of their products [5]

JP Morgan 44th Annual Healthcare Conference Frank D. Lee Chief Executive Officer PCRX | January 14, 2026 Forward-looking statements and where to find additional information Any statements in this presentation about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "may," "plan," "project," "should," "will," "would," and similar expressions, constitute forward-look ...

Core Insights - Pacira BioSciences has partnered with LG Chem to expand access to opioid-sparing postsurgical pain control in select Asia-Pacific markets through the exclusive commercialization of EXPAREL [1][2] Company Overview - Pacira BioSciences is focused on delivering innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera® [3] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management techniques [3] - ZILRETTA is an extended-release injectable for osteoarthritis knee pain management [3] - Iovera® is a handheld device providing immediate, long-acting, drug-free pain control [3] - The company is advancing a pipeline of clinical-stage assets, including PCRX-201, a gene therapy for osteoarthritis of the knee in Phase 2 development [3] Partnership Details - LG Chem will have exclusive rights to commercialize EXPAREL in the designated territories, leveraging its experience in orthopedic pain management [2] - Pacira will receive an undisclosed upfront payment, a transfer price, and tiered royalties on future sales by LG Chem [2] - LG Chem is responsible for obtaining regulatory approvals in the licensed territories, with plans to file for marketing authorizations in South Korea and Thailand within six months [2]

Core Insights - Pacira BioSciences reported record-high total revenue of $726.4 million for the year ended December 31, 2025, representing an increase from $701.0 million in 2024, driven by strong sales of EXPAREL and share repurchase activities [1][4][6] Revenue Highlights - Fourth quarter EXPAREL net product sales reached $155.8 million in 2025, up from $147.7 million in 2024, with a volume growth of 7 percent [8] - Full-year EXPAREL net product sales were $575.1 million in 2025, compared to $549.0 million in 2024, reflecting a 6 percent volume growth [8] - Fourth quarter ZILRETTA net product sales were $33.0 million in 2025, slightly down from $33.1 million in 2024 [8] - Fourth quarter iovera° net product sales increased to $7.0 million in 2025 from $6.5 million in 2024 [8] - Other revenue, including sales of bupivacaine liposome injectable suspension, was $1.1 million in the fourth quarter of 2025, compared to zero in the same period of 2024 [8] Share Repurchase Program - During the fourth quarter of 2025, the company repurchased 2.0 million shares of its common stock for $50.0 million, with $150.0 million remaining on its current share repurchase authorization [6] Strategic Outlook - The CEO emphasized the company's solid execution and progress in advancing its strategic priorities, positioning it for sustainable long-term success and significant revenue growth moving forward [2]

Core Insights - Pacira Biosciences has joined the PROBE Consortium to enhance osteoarthritis research and patient care globally, leveraging data from over 70 million individuals [1][3] - The initiative aims to address significant unmet needs in osteoarthritis treatment, particularly due to a lack of innovation since the introduction of ZILRETTA [2][3] Company Overview - Pacira specializes in innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera [4] - ZILRETTA is the first and only extended-release intra-articular therapy approved for osteoarthritis knee pain, providing pain relief for up to 16 weeks [5] PROBE Consortium Objectives - The PROBE initiative includes 38 partners from various sectors, aiming to transform osteoarthritis diagnosis and treatment through improved data analysis and trial designs [3][7] - Key strategies include creating a regulation-compliant database network, utilizing AI for disease progression predictions, and developing novel trial endpoints [7]

Business Growth - Pacira treated more than 3 million patients per year[4,6,8] - The company is experiencing double-digit compounded annual growth rate in product revenue[4,9] - EXPAREL volume growth in 3Q25 reached 9% year-over-year, marking the highest volume growth in over 3 years[9] - Pacira anticipates product revenue to exceed $1.1 billion by 2030[9] Profitability - Pacira achieved a 5-percentage point gross margin improvement over 2024[4,10] - The company's non-GAAP gross margins are projected to be between 80% and 82%[11,42] Pipeline and Partnerships - Pacira is expanding its clinical pipeline with 5 novel programs in development[4,12] - The company is establishing 5 partnerships, including pipeline and commercial agreements[4,14] Financial Performance - Total revenue for 3Q25 was $180 million[42] - Adjusted EBITDA for 3Q25 was $49 million[42] - The company's cash and investments stand at approximately $246 million[42]

Core Insights - Pacira BioSciences has announced an exclusive worldwide license and collaboration agreement with AmacaThera for the development of AMT-143, a novel long-acting formulation of the non-opioid analgesic ropivacaine aimed at postsurgical pain control [1][2] Company Strategy - The addition of AMT-143 to the pipeline aligns with Pacira's 5x30 growth strategy, focusing on clinical stage, derisked opportunities that complement existing pain management offerings [2] - The company aims to enhance its leadership in opioid-sparing pain management through this new asset, which is expected to improve patient outcomes and expand treatment options [2] Financial Terms of the Agreement - Under the agreement, Pacira will fund the clinical development up to commercial launch, with AmacaThera receiving an upfront payment of $5 million, along with potential future milestone payments and a tiered royalty on net sales [3] Product Details - AMT-143 is designed for postsurgical pain control and demonstrated sustained release of ropivacaine for up to 14 days in a Phase 1 study [4] - The product utilizes AmacaThera's hydrogel-based drug delivery platform, which allows for slow release while minimizing systemic side effects [5] Current Product Portfolio - Pacira currently offers three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera, which target various pain management needs [6]

Core Insights - Pacira BioSciences, Inc. is presenting real-world evidence on the clinical effectiveness and economic benefits of EXPAREL at the AMCP Nexus 2025 Annual Meeting [1][3] - The company aims to advance understanding of postsurgical pain management and reduce reliance on opioids through multimodal pain pathways [3] Company Overview - Pacira specializes in innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera [5] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management applications [5][6] - The company is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [5] Research Presentations - The AMCP Nexus 2025 will feature presentations on the impact of liposomal bupivacaine on healthcare resource utilization and costs in total knee arthroplasty [4] - Additional presentations will cover outcomes related to intraoperative liposomal bupivacaine and its effects on opioid use and functional outcomes [7] Product Details - EXPAREL utilizes multivesicular liposome technology to deliver bupivacaine over time, achieving significant reductions in cumulative pain scores and opioid consumption [8] - The product is indicated for postsurgical local and regional analgesia in patients aged 6 years and older [6]

Financial Data and Key Metrics Changes - The net loss attributable to common stockholders for Q2 2025 was approximately $24.5 million, compared to approximately $9.7 million for the same period in 2024, indicating a significant increase in losses [33] - Research and development expenses totaled approximately $5.8 million for Q2 2025, down from approximately $7.1 million in Q2 2024 [33] - General and administrative expenses were approximately $2.3 million for Q2 2025, compared to approximately $2.8 million for the same period in 2024 [33] - The impairment of acquired in-process research and development intangible assets was $16.5 million, compared to zero during the same period in 2024 [34] - As of June 30, 2025, the company had cash and cash equivalents of approximately $33.4 million, which is expected to fund operations into 2026 [34] Business Line Data and Key Metrics Changes - The phase two MINDFUL trial for EXPAREL confirmed that Alzheimer's patients with two or more biomarkers of inflammation are optimal candidates, with an estimated 40% to 60% of all Alzheimer's cases fitting this profile [7][8] - In the key subgroup of patients with high inflammation, the trial observed an effect size of 0.27 on the primary endpoint EMAC and 0.23 on a key secondary behavioral endpoint, the neuropsychiatric inventory [15][16] - The company has decided not to pursue treatment-resistant depression at this time and is reevaluating opportunities for EXPAREL beyond Alzheimer's disease [10][11] Market Data and Key Metrics Changes - The company anticipates filing for approval of Cordstrom in both the UK and US by mid-2026, with expectations that it will qualify for a Priority Review Voucher if approved in the US [12] - The company is exploring shorter pathways to market for EXPAREL, including opportunities in rare diseases to maximize impact and accelerate patient access [9] Company Strategy and Development Direction - The company is focused on securing strategic partnerships to advance the EXPAREL program, which requires substantial investment in manufacturing and clinical trials [8][9] - The company aims to prepare for an end of phase two meeting with the FDA to align on the design of the phase three trial for EXPAREL [21] - The company is committed to exploring strategic partnerships to fuel growth and complete trials, while also ensuring the development of Cordstrom and INKmune [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of EXPAREL as a first-in-class drug for Alzheimer's disease, emphasizing its unique approach to addressing neuroinflammation [7][8] - The management highlighted the importance of the recent phase two trial results and the potential for strategic partnerships to support the program's advancement [22] - Management acknowledged the challenges of the current operating environment but remains optimistic about the company's robust pipeline and potential value creation [36] Other Important Information - The company plans to publish the trial results in a peer-reviewed journal and prepare a briefing book for the FDA meeting, expected to occur before the end of the year [35] - The company is actively exploring additional indications for Cordstrom beyond recessive dystrophic epidermolysis bullosa [12][26] Q&A Session Summary Question: Confirmation of end of Phase two meeting date with FDA - The specific meeting date has not been set yet, and the briefing book is being prepared [41] Question: Atmosphere at AAIC and feedback from thought leaders - Feedback was positive, with strong interest in the neuropsychiatric inventory and the absence of amyloid-related imaging abnormalities [42][44] Question: Strategic partnerships for EXPAREL - A partnership is not expected until after the end of phase two meeting with the FDA, as partners will want to see the publication and FDA feedback first [46][48] Question: Insights from ongoing statistical analysis for Cordstrom - The statistical analysis plan is expected to yield improved data for submission, and the open-label trial is planned for early 2027 [70][72]